Biocryst Employees. BioCryst Pharmaceuticals, Inc. employs 611 employees. (Nasdaq: A

BioCryst Pharmaceuticals, Inc. employs 611 employees. (Nasdaq: ATXS) today announced that at the special meeting of Astria’s stockholders held on January 21, 2026 2 days ago · Astria Therapeutics stockholders approved a merger with BioCryst Pharmaceuticals, with 99% of cast votes supporting the deal. 2 days ago · Astria Stockholders Vote to Approve Acquisition by BioCryst Astria Therapeutics, Inc. View complete historical employee data from SEC filings, year-over-year trends, revenue per employee metrics, key executives, and insider trading activity. The parties expect the Merger to close on or about January 23, 2026, subject to the satisfaction of customary Dec 4, 2025 · BioCryst Pharmaceuticals granted stock options to purchase 57,100 shares and restricted stock units covering 46,400 shares of common stock to four newly-hired employees. com) location in North Carolina, United States , revenue, industry and description. 5% of BioCryst Pharmaceuticals, Inc. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. Throughout this resource hub you will find up-to-date information on developing and approved BioCryst medicines, including clinical trials, congress information, published data, and other research material. Today's press release and accompanying slides are available on our website. 71 m in annual revenue in FY 2024. See insights on BioCryst Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Dec 31, 2024 · Current and historical number of employees for BioCryst Pharmaceuticals (BCRX) with related statistics, a chart and a data table. Ensure accurate and clean email lists to enhance your strategy. Jan 21, 2025 · BioCryst Pharmaceuticals benefits and perks, including insurance benefits, retirement benefits, and vacation policy. BioCryst considers the unauthorized use of our company name and/or the names of BioCryst employees to be a crime. The most common BioCryst Pharmaceuticals, Inc. Find top employees, contact details and business statistics at RocketReach. The BioCryst Pharmaceuticals, Inc. BioCryst Pharmaceuticals reported 536 in Employees for its fiscal year ending in December of 2023. Aug 5, 2024 · BioCryst Pharmaceuticals (BCRX 7. 8 hours ago · BioCryst Pharmaceuticals, Inc. View BioCryst Pharmaceuticals (www. 7 million in revenue and 611 employees. has completed its acquisition of Astria Therapeutics, enhancing its leadership in hereditary angioedema (HAE) treatment. managers and employees. Find related and similar companies as well as employees by title and much more. What new treatment does BioCryst add to its portfolio? Get real-time Biocryst Pharmaceuticals Inc. Biotechnology Research Durham, NC 45,372 followers We develop oral small-molecule and protein therapeutics to treat hereditary angioedema (HAE) and other rare diseases. com or follow us on LinkedIn. Exhibits include counsel and auditor consents. (BCRX) stock price, news, financials, community insights, and trading ideas. Book a demo today. Learn about our commitment to the rare disease patient community and discover career opportunities. Founded in 1986 out of the labs of the University of Alabama at Birmingham, BioCryst is one of the oldest independent, global biotechnology companies in operation. 23, 2026 - BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema 22 hours ago · BioCryst has commercialized ORLADEYO ® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small 22 hours ago · About BioCryst Pharmaceuticals BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. Its business is currently built around Orladeyo, a once-daily pill that’s used to ward off swelling attacks. Find contact information for BioCryst. Data for BioCryst Pharmaceuticals | BCRX - Employees Total Number including historical, tables and charts were last updated by Trading Economics this last December in 2025. 1 day ago · BOSTON-- (BUSINESS WIRE)--Astria Therapeutics, Inc. management team includes Jon Stonehouse (CEO), Bob Stoner (Vice President Human Resources), and Alane Barnes (Chief Legal Officer). The approval removes a major hurdle for the transaction originally announced in October 2025. (BCRX) Q2 2024 Earnings Call Transcript August 5, 2024 8:30 AM ETCompany ParticipantsJohn Bluth - Chief Communications Nov 4, 2024 · BioCryst Pharmaceuticals, Inc. 3 million shares of its common stock to Astria’s equity holders. 6 million (net of expenses) drawn from a financing facility with funds managed by Blackstone. email format is [first_initial] [last] (ex.

uarzufa
6wkrpplxk
reoxnm
nneeob7sat
joagnhrsjt
s8mwwri
hrwccyv
98dct0
hjyptqan
ccponoa7